Why the Tryngolza decision matters for Swedish Orphan Biovitrum
NICE’s final draft guidance recommending Tryngolza for adults with familial chylomicronaemia syndrome puts Swedish Orphan Biovitrum (OM:SOBI) in focus. The decision follows positive Phase 3 Balance trial data on triglycerides and acute pancreatitis.
Swedish Orphan Biovitrum’s latest share price of SEK433.4 comes after a 1-day share price return of 1.12%, while the 30-day share price performance is down 3.69% and the 90-day move is down 9.48%, suggesting recent momentum has faded even though the year-to-date share price return of 31.17% and 1-year total shareholder return of 38.82% point to a stronger longer term trend.
Scan how Swedish Orphan Biovitrum compares with other rare disease and specialist treatment players by reviewing our hand picked 619 high quality undiscovered gems in the wider healthcare space.
Recent weakness over 1 and 3 months contrasts with strong 1 and 3 year gains, which raises a simple question: Are you watching sentiment cool or Swedish Orphan Biovitrum’s fundamentals finally catch up with its price?
Most Popular Narrative: 13% Undervalued
Swedish Orphan Biovitrum’s most followed narrative pegs fair value at SEK498.42 using a 5.55% discount rate, which sits above the latest SEK433.4 close and frames the current valuation debate after the Tryngolza update.
The successful launch and rapid adoption of Altuvoct in markets like Germany, where it achieved a 57% market share within 9 months, present a significant opportunity for market share growth in Europe, potentially boosting future revenues. The expected regulatory approvals and market entries for Aspaveli in nephrology indications and Gamifant in secondary HLH show potential for new revenue streams, as these products address unmet medical needs in growing markets.
See why 11 investors see Swedish Orphan Biovitrum as 13% undervalued.
Result: Fair Value of SEK498.42 (UNDERVALUED)
Still, Swedish Orphan Biovitrum’s story can change quickly if reimbursement delays for launches like Altuvoct or tougher competition for Aspaveli affect growth assumptions.
Find out about the key risks to this Swedish Orphan Biovitrum narrative.
Another View on Swedish Orphan Biovitrum’s Valuation
Analyst fair value and price targets point to Swedish Orphan Biovitrum looking underpriced, yet the market is telling a different story through its P/E. The stock trades on 109.1x earnings versus 53.8x for peers and a fair ratio of 57.8x, which signals a rich multiple that could compress if expectations slip.
To see how those earnings multiples stack up against the underlying numbers, and where valuation pressure might build next, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Curious whether the optimism around Swedish Orphan Biovitrum really outweighs the concerns flagged so far? Act while the Tryngolza news is still fresh and weigh the upside against the caution signs by reviewing the 2 key rewards and 3 important warning signs.
Looking for more Swedish Orphan Biovitrum sized ideas?
If you want Swedish Orphan Biovitrum to be one of several strong candidates rather than your only focus, broaden your watchlist using targeted screeners now.
- Target resilience first by reviewing a list of solid balance sheet and fundamentals (207 results) that can better weather shocks and keep funding growth without stretching their finances.
- Focus on quality at a reasonable entry point with a 184 high quality undervalued stocks that combines solid fundamentals with prices that do not fully reflect their financial profile.
- Build a calmer portfolio core using a 225 resilient stocks with low risk scores designed to limit unpleasant surprises while still keeping you exposed to potential upside.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com